We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
MDMA and psilocybine are controlled substances regulated as therapeutic goods in Australia. These are unapproved therapeutic goods, meaning they are not included in the Australian Register of Therapeutic Goods (ARTG) and have not been assessed by us for safety, quality or effectiveness.
Access to MDMA and psilocybine requires authorisation via the Authorised Prescriber Scheme.
Access is restricted to psychiatrists who have been authorised under this pathway. Sponsors must ensure all supply complies with relevant legislative requirements.
MDMA and psilocybine can also be accessed through clinical trials. For further information on how to access MDMA and psilocybine through clinical trials, please refer to Clinical trials.
You must meet certain obligations to legally supply therapeutic goods in Australia. This section contains guidance and information specific to unapproved therapeutic goods. You may also have to meet obligations that apply to all products.